Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Relmada Therapeutics ( (RLMD) ) has issued an announcement.
Relmada Therapeutics has entered into an Asset Purchase Agreement with Asarina Pharma AB to acquire Sepranolone, a Phase 2b ready neurosteroid being developed for Tourette Syndrome and other compulsive disorders, for €3 million. This acquisition aligns with Relmada’s strategy to enhance its CNS disorder treatment portfolio, as Sepranolone has shown promising Phase 2a results, offering significant tic reduction and quality of life improvements without serious side effects, potentially positioning it as a first-line treatment for Tourette Syndrome.
More about Relmada Therapeutics
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for central nervous system (CNS) and metabolic disorders. The company is committed to advancing breakthrough treatments to improve patient outcomes and quality of life.
YTD Price Performance: -15.56%
Average Trading Volume: 1,121,053
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.47M
Find detailed analytics on RLMD stock on TipRanks’ Stock Analysis page.
